- Gilead Sciences (GILD -4.7%) is sharply lower despite issuing strong Q4 results, as investors appear focused on the company's forecast which didn’t include projections for its new Sovaldi hepatitis-C drug.
- ISI Group says the failure to give Sovaldi sales guidance is worrying investors, even though GILD is known to be conservative; he also says operating expense guidance for 2014 was higher than anticipated, and the company has changed its tune about who is taking Sovaldi, perhaps suggesting an increased risk of a sales slowdown later this year before the Sovaldi/ledispavir launch.
- Elliot Favus offers some reasons to sell the stock, including little margin for error for the Sovaldi launch with expectations already sky high, and a shareholder base which has become too generalized and don't understand hepatitis-C.